Literature DB >> 10385717

Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice.

M Alikhan1, D Rex, A Khan, E Rahmani, O Cummings, T M Ulbright.   

Abstract

BACKGROUND: Pathologic interpretation of biopsy specimens of columnar lined esophagus guides subsequent endoscopic surveillance and/or surgical intervention. The aim of this study was to evaluate pathologic interpretation of columnar lined esophagus by general pathologists in community practice.
METHODS: Five histologic slides representing different types of columnar lined esophagus were submitted for review by 20 randomly selected general pathologists in community practice. There were three cases with intestinal metaplasia (one with no dysplasia, one with low-grade dysplasia, and one with high-grade dysplasia) and two cases of gastric metaplasia (one fundic-type and one cardia-type).
RESULTS: High-grade dysplasia was identified as such by 30% of pathologists and was called invasive adenocarcinoma by 20%, low-grade dysplasia by 30%, and moderate dysplasia by the remaining 20%. Low-grade dysplasia was identified as such by 35% of pathologists and was called high-grade dysplasia by 20%, moderate dysplasia by 20%, and no dysplasia by 25%. Specialized columnar epithelium with no dysplasia was identified as such by 35%, called low-grade dysplasia by 35%, moderate dysplasia by 15%, indeterminate for dysplasia by 10%, and invasive adenocarcinoma by 5%. Gastric metaplasia without specialized columnar epithelium was identified as Barrett's esophagus in 38% of cases.
CONCLUSIONS: Pathologic interpretation of columnar lined esophagus by community pathologists may be subject to marked interobserver variation. The term Barrett's esophagus is often used to describe columnar lined esophagus without goblet cells. Because this finding is not clearly associated with an increased risk of cancer, these data support recent suggestions that the term Barrett's esophagus be abandoned. Interpretations of both high-grade and low-grade dysplasia should be considered for review by experts in esophageal pathology.

Entities:  

Mesh:

Year:  1999        PMID: 10385717     DOI: 10.1016/s0016-5107(99)70339-1

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  46 in total

1.  Biomarkers in exploring the frontiers of diagnosis, prognosis, and therapy of Barrett's esophagus.

Authors:  Patrick Yachimski; Richard M Peek
Journal:  Cancer Prev Res (Phila)       Date:  2011-06

2.  Barrett's oesophagus: time for consensus.

Authors:  G Faller; M Stolte
Journal:  Virchows Arch       Date:  2003-10-09       Impact factor: 4.064

3.  What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.

Authors:  N J Shaheen; J M Inadomi; B F Overholt; P Sharma
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

Review 4.  Early events during neoplastic progression in Barrett's esophagus.

Authors:  Brian J Reid
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

Review 5.  Esophageal resection for high-grade dysplasia and intramucosal carcinoma: When and how?

Authors:  Vani J A Konda; Mark K Ferguson
Journal:  World J Gastroenterol       Date:  2010-08-14       Impact factor: 5.742

6.  Towards the molecular characterization of disease: comparison of molecular and histological analysis of esophageal epithelia.

Authors:  Daniel Vallböhmer; Paul Marjoram; Hidekazu Kuramochi; Daisuke Shimizu; Hsuan Jung; Steve R DeMeester; Daniel Oh; Parakrama T Chandrasoma; Kathleen D Danenberg; Tom R DeMeester; Peter V Danenberg; Jeffrey H Peters
Journal:  J Gastrointest Surg       Date:  2007-09       Impact factor: 3.452

Review 7.  Barrett's oesophagus: from metaplasia to dysplasia and cancer.

Authors:  J-F Fléjou
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

Review 8.  [Correct diagnosis for indication in gastroesophageal reflux disease].

Authors:  A H Hölscher; E Bollschweiler; Ch Gutschow; P Malfertheiner
Journal:  Chirurg       Date:  2005-04       Impact factor: 0.955

Review 9.  Gastroesophageal reflux and Barrett's esophagus: a pathway to esophageal adenocarcinoma.

Authors:  Francisco Schlottmann; Daniela Molena; Marco G Patti
Journal:  Updates Surg       Date:  2018-07-23

10.  Expert pathology review and endoscopic mucosal resection alters the diagnosis of patients referred to undergo therapy for Barrett's esophagus.

Authors:  Katie Ayers; Chanjuan Shi; Kay Washington; Patrick Yachimski
Journal:  Surg Endosc       Date:  2013-02-07       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.